HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine ...

There has been expectation that the antibody could be made available at a discount to Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), which dominates first-line NSCLC treatment, offering an ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

Agenus (AGEN) announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab in combination with ...

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...